Latest News
ZipRecruiter has closed a USD63 million Series A funding round led by Institutional Venture Partners (IVP) with participation from Basepoint and Industry Ventures.
Proceeds from the round will be used to develop new products, accelerate marketing for future growth, selectively pursue acquisitions and scale the infrastructure.
IVP principal Eric Liaw will be joining the ZipRecruiter board of directors.
ZipRecruiter launched in 2010 with the goal of bringing Fortune 500-level recruiting tools to every small and medium sized business in North America. In 2014, ZipRecruiter is on pace to exceed 100 per cent revenue growth and registers over 30,000
Paul Hastings has advised Ocean Holding on the acquisition of the Düsseldorfer Hypothekenbank, a German mortgage bank, from the US investor Lone Star.
Measured by total assets estimated at EUR12 billion, this is the largest German bank takeover since the start of the financial crisis.
Ocean Holding, a fund managed by Patrick Bettscheider and Attestor Capital, has acquired Düsseldorfer Hypothkenbank from the previous owners, LSF5 German Investments II LP, Delaware, and LSF5 Riverside Ltd & Co KG, two companies of the Lone Star Group.
The Lone Star Group acquired the bank in 2010 and injected more than EUR500
Brentwood Associates, a consumer-focused private equity investment firm, has acquired Marshall Retail Group, headquartered in Las Vegas, Nevada.
Marshall Retail Group is a specialty retailer for high-foot-traffic marketplaces with locations in major casino-hotels and airports across the US. The company is led by chief executive officer Michael C Wilkins, who will continue to lead the business going forward.
Founded in 1955, Marshall Retail Group operates 155 retail locations across 10 states and Washington DC.
Wilkins says: “Brentwood is an important strategic partner that truly understands our business. We are eager to call on their expertise in retail and
Venture capital (VC) funding for the life sciences sector, which includes biotechnology and medical devices, reached USD2.5 billion in 195 deals for the second quarter of 2014, according to a report.
The report, which includes data from the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), and is based on data provided by Thomson Reuters, reveals that while Q2 saw the highest level of investment since the second quarter of 2007, it was also the strongest second quarter since 1995, which is the earliest data recorded by the MoneyTree.
During the second quarter of 2014,
Riverstone Holdings will be one of three cornerstone investors in new Norway and UK-focused exploration and production (E&P) company Origo Exploration.
Riverstone and Barclays Natural Resource Investments (BNRI) will each contribute USD200 million of funding to Origo, while Singapore-based investment company Temasek will contribute an additional USD125 million.
The Riverstone commitment comprises USD133 million from Riverstone Global Energy and Power Fund V and USD67 million from Riverstone Energy Limited (REL).
Origo, headquartered in Stavanger, is led by Andrew Armour, Timothy Sullivan, Svein Ilebekk, Kent Høgseth and Ørjan Gjerde, all highly-experienced professionals from the E&P industry in Norway and
KKR has appointed Jaka Prasetya, former managing partner and founder of Leafgreen Capital Partners, as managing director to lead the firm’s Indonesia efforts as well as credit and special situations initiatives in Southeast Asia.
Also joining KKR in the role of director are Rahul Bhargava and Allan So, both formerly managing directors and partners at Leafgreen, a provider of mezzanine and structured growth funding in Southeast Asia.
Prasetya, Bhargava and So will be based in Singapore. The appointments are effective 26 August 2014.
Prasetya will work with KKR’s private equity, credit and special situations teams to enhance the
Early-stage venture capital firm Amplify Partners has appointed Mike Dauber as general partner.
He joins from Battery Ventures, where he spent over six years driving investments in enterprise infrastructure and applications.
In his new role, Dauber will continue to fund and support the next generation of enterprise technology entrepreneurs.
"Having worked side by side as his colleague at Battery Ventures, and then again as his co-investor at Amplify Partners, I know Mike's talent, drive and commitment to helping entrepreneurs are second to none," says Sunil Dhaliwal, founder and general partner, Amplify Partners. "Mike will be a cornerstone of
Edmond de Rothschild Investment Partners’ (EdRIP) BioDiscovery 3 portfolio company, Sapiens Steering Brain Stimulation (Sapiens SBS), has been acquired by Medtronic for approximately USD200 million in cash.
Sapiens SBS, located in Eindhoven, The Netherlands, is developing a DBS system that features an advanced DBS lead with 40 individual stimulation points. This advanced system is designed to allow more precise stimulation of the intended target in the brain and may potentially result in reduced procedure time and fewer stimulation-induced side effects.
Employees at the Eindhoven facility will continue to work toward bringing this technology to market. In the future, the
Jason D Osborn has joined Jenner & Block’s private equity and mergers and acquisitions practices as a corporate partner in the Chicago office.
An experienced private equity lawyer, Osborn will focus on representing private equity funds and public and private company clients in complex transactions, including mergers and acquisitions, leveraged buyouts, going-private transactions, joint ventures, divestitures, private financings, recapitalisations and restructurings, and in related corporate governance, executive compensation and general corporate matters.
“The firm is committed to growing our corporate practice with talented lawyers of the highest calibre,” says Jenner & Block managing partner Terrence J Truax. “Jason’s transactional
Edmond De Rothschild Investment Partners’s (EdRIP) BioDiscovery 3 portfolio company, Covagen AG, has been acquired by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Company.
Covagen is a privately-held, biopharmaceutical company specialising in the development of multi-specific protein therapeutics through the FynomAb technology platform. The company's lead product, COVA322, a bispecific anti-tumour necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb is in Phase 1b study for psoriasis and holds potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis.
Covagen develops FynomAbs, multi-specific protein therapeutics by fusing its fully human Fynomer binding proteins to antibodies. Fynomers are
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
